Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2025-12-27 @ 6:47 AM
Study NCT ID:
NCT05064059
Status:
COMPLETED
Last Update Posted:
2025-09-17
First Post:
2021-09-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-10
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-02-21
Completion Date Type:
ACTUAL
First Submit Date:
2021-09-29
First Submit QC Date:
None
Study First Post Date:
2021-10-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-07-31
Results First Submit QC Date:
None
Results First Post Date:
2025-09-17
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-28
Last Update Post Date:
2025-09-17
Last Update Post Date Type:
ESTIMATED